Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Lee

Internal Medicine Chicago, IL Medical Doctor

NPI 1942293451 CMS profile 532635

676 N Saint Clair St, Suite 2300, Chicago, IL 60611

Open in the dashboard

General payments

$6,214

271 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Lee of Chicago, IL is reported in the CMS Open Payments database as having received $6,214 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,385 55
2024 General $1,558 57
2023 General $1,242 52
2022 General $562 24
2021 General $100 5
2020 General $246 15
2019 General $1,122 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Lee
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michael Lee were reported at $1,385. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michael Lee Internal Medicine median Middle half National median
2019 $1,122 $159 $48–$570 $163
2020 $246 $119 $33–$402 $114
2021 $100 $135 $37–$521 $132
2022 $562 $141 $42–$496 $149
2023 $1,242 $149 $45–$519 $160
2024 $1,558 $154 $47–$537 $164
2025 $1,385 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,167 49 payments
  2. Novo Nordisk Inc $800 37 payments
  3. Amgen Inc. $632 31 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $534 22 payments
  5. AbbVie, Inc. $492 14 payments
  6. Gilead Sciences, Inc. $444 19 payments
  7. AstraZeneca Pharmaceuticals LP $325 22 payments
  8. Exact Sciences Corporation $247 10 payments
  9. Merck Sharp & Dohme Corporation $225 11 payments
  10. Lilly USA, LLC $196 9 payments
  11. Other $1,153 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,214 271 payments
Products named General payments · program years 2019–2025
  1. PREVNAR 20 $389 15 payments
  2. ELIQUIS $388 16 payments
  3. COMIRNATY $361 14 payments
  4. EVENITY $298 14 payments
  5. Ozempic $293 14 payments
  6. ABRYSVO $289 11 payments
  7. Wegovy $273 12 payments
  8. UBRELVY $251 9 payments
  9. NURTEC ODT $249 11 payments
  10. Prolia $229 11 payments
  11. Other $4,848 220 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,914

Median for Internal Medicine: 777

Drug cost

$152,149

Median for Internal Medicine: $73,373

Branded share of claims

11.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $37,923
Jardiance Empagliflozin Brand 25 $30,492
Xarelto Rivaroxaban Brand 26 $25,876
Ozempic Semaglutide Brand 12 $20,949
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $9,811
Rosuvastatin Calcium Generic 216 $2,992
Atorvastatin Calcium Generic 195 $2,680
Metoprolol Succinate Generic 152 $2,450
Tamsulosin Hcl Generic 88 $1,674
Amlodipine Besylate Generic 168 $1,467

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$58,555

Of which drugs: $10,288

Medicare patients

173

Average age 75

Services billed

945

69 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 24%
Cancer 21%
Diabetes 15%
Atrial fibrillation 15%
Ischemic heart disease 14%
Osteoporosis 13%
Depression 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 11 11 $3,158
Sarscv2 vac 30mcg trs-suc im 91320 Office 20 20 $3,056
Vaccine for influenza for injection into muscle 90653 Office 22 22 $1,800

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOQTORZI
$125 — —
JARDIANCE
$118 25 —
Wegovy
$101 — —
EVENITY
$70 — —
NURTEC ODT
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record